GlassScriptPhysician profile
David L Gaston
NPI 1811000227
$1,611.63
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $342 · 2021: $365 · 2022: $146 · 2023: $230 · 2024: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $523.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $538.44 | 2020-2023 | Austedo, Uzedy |
| Biogen, INC. | $401.30 | 2019-2022 | |
| Ucb, INC. | $220.74 | 2019-2024 | Briviact |
| Inari Medical, INC. | $167.50 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Lilly USA, LLC | $131.51 | 2019-2021 | |
| Genzyme Corporation | $53.29 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $27.45 | 2020-2021 | |
| Aquestive Therapeutics, INC. | $17.18 | 2019 | |
| Allergan, INC. | $16.31 | 2020 | |
| Celgene Corporation | $14.04 | 2021 | |
| Neurocrine Biosciences, INC. | $12.72 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gaston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.